文献速递妇科

p53异常子宫内膜癌患者基于超声测量的子宫内膜厚度评估

Ultrasonography-Based Measurements of Endometrial Thickness in Patients With p53 Abnormal Endometrial Carcinomas.
PubMed 文献 · Obstet Gynecol · 2025-10-02

这项回顾性队列研究纳入2004至2017年确诊子宫内膜癌且诊断前接受经阴道超声(TVUS)的患者133例,按p53状态分层。p53异常组子宫内膜厚度中位数10 mm,低于p53野生型组的18 mm(P<.001);以4 mm为阈值,p53异常组假阴性率25%,高于p53野生型组的4.1%(P<.001)。作者认为TVUS测量子宫内膜厚度作为p53异常子宫内膜癌的筛查方法似乎不可靠。

要点

  • p53异常子宫内膜癌患者子宫内膜厚度中位数为10 mm,p53野生型为18 mm(P<.001)。
  • 以4 mm为阈值,p53异常组假阴性率25%,p53野生型组为4.1%(P<.001)。
  • p53状态(OR 9.415)和较低BMI(OR 0.906)与假阴性筛查结果独立相关。

核心结论

  • 经阴道超声评估的子宫内膜厚度似乎不是p53异常子宫内膜癌患者的可靠筛查方法。
  • 以子宫内膜厚度筛查子宫内膜癌可能因假阴性结果而漏诊相当比例的p53异常病例。
  • 出现绝经后出血时,应强烈考虑进行子宫内膜组织取样。

研究设计与样本

  • 回顾性队列研究,纳入2004至2017年间确诊子宫内膜癌且诊断前接受经阴道超声(TVUS)的患者133例。
  • 采用组织微阵列按p53免疫组化染色异常与否分为p53异常组(60例,45.1%)和p53野生型组(73例,54.9%)。
  • 按绝经后出血评估所用的4 mm子宫内膜厚度筛查阈值进行分层。
  • 所有患者均接受包括子宫切除术在内的手术分期。

主要发现

  • 队列中位年龄66岁(四分位距58-74岁),中位体重指数(BMI)31.3(四分位距26.8-37.3)。
  • 中位子宫内膜厚度16 mm(四分位距9-22 mm),48例(36.1%)经TVUS发现黏膜下或肌壁间子宫肌瘤。
  • p53异常子宫内膜癌患者子宫内膜厚度测量值较p53野生型更薄:10 mm(四分位距5-18.5 mm)vs 18 mm(四分位距13-23 mm),P<.001。
  • 以4 mm或以下为阈值,p53异常子宫内膜癌患者筛查阴性比例高于p53野生型患者:25% vs 4.1%,P<.001。
  • 多因素分析中,子宫内膜厚度4 mm或以下阈值、较低BMI(OR 0.906,95%CI 0.833-0.986,P=.023)和p53状态(OR 9.415,95%CI 2.441-36.309,P=.001)仍为假阴性筛查结果的显著预测因素。

关键数值与推荐

  • 采用4 mm或以下子宫内膜厚度作为绝经后出血评估的筛查阈值。
  • 假阴性TVUS筛查结果定义为子宫内膜厚度4 mm或以下。

临床怎么用

  • 作者认为经TVUS评估的子宫内膜厚度似乎不是p53异常子宫内膜癌患者的可靠筛查方法。
  • 作者指出以子宫内膜厚度筛查子宫内膜癌可能因假阴性结果而漏诊相当比例的p53异常病例。
  • 作者建议出现绝经后出血时,应强烈考虑进行子宫内膜组织取样。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate prediagnostic endometrial thickness measured by transvaginal ultrasonography (TVUS) in a cohort of patients with endometrial cancer stratified by p53 status to assess accuracy of endometrial thickness as a screening tool in this patient population. METHODS: We conducted a retrospective cohort study of patients diagnosed with endometrial cancer who underwent prediagnostic TVUS between 2004 and 2017. Using a tissue microarray, we categorized cases as p53 abnormal (p53abn) or p53 wild type (p53wt) according to the presence or absence of p53 aberrant immunohistochemistry staining. Cases were stratified according to established screening thresholds of 4-mm or less endometrial thickness used to evaluate postmenopausal bleeding. Clinical data were manually abstracted. All patients included underwent surgical staging, including hysterectomy. Student t , χ 2 , and Fisher exact tests were performed to assess for variables associated with p53abn endometrial carcinoma. Multivariate logistic regression was performed to assess variables associated with cases of endometrial cancer, with false-negative TVUS screening results defined as an endometrial thickness of 4 mm or less. RESULTS: Of the 133 patients identified, 60 (45.1%) were classified as p53abn and 73 (54.9%) as p53wt. The median age of the cohort was 66 years (interquartile range 58-74 years), and median body mass index (BMI) was 31.3 (interquartile range 26.8-37.3). Median endometrial thickness was 16 mm (interquartile range 9-22 mm), and 48 patients (36.1%) had submucosal or intramural leiomyomas identified on TVUS. Patients diagnosed with p53abn endometrial cancers were more likely to have thinner endometrial measurements compared with p53wt cases (10 mm [interquartile range 5-18.5 mm] vs 18 mm [interquartile range 13-23 mm], P <.001). At a threshold of 4 mm or less, patients with p53abn endometrial cancer were more likely to screen negative compared with patients with p53wt endometrial cancer (25% vs 4.1%, P <.001). In multivariate analysis, a threshold of 4 mm or less for endometrial thickness, lower BMI (odds ratio [OR] 0.906, 95% CI, 0.833-0.986, P =.023), and p53 status (OR 9.415, 95% CI, 2.441-36.309, P =.001) remained significant predictors of false-negative screening results. CONCLUSION: Endometrial thickness assessed by TVUS does not appear to be a reliable screening method in patients diagnosed with p53abn endometrial cancers. The use of endometrial thickness as a screening test for endometrial cancer may miss a significant portion of p53abn cases because of false-negative results. In the presence of postmenopausal bleeding, endometrial tissue sampling should be strongly considered.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Wagar MK, Mojdehbakhsh RP, Reetz E, et al. Ultrasonography-Based Measurements of Endometrial Thickness in Patients With p53 Abnormal Endometrial Carcinomas. Obstet Gynecol. 2025. PMID: 41037814. doi:10.1097/AOG.0000000000006074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。